LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update
LVTXUTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or the “Company”), a clinical-stage immuno-oncology company historically focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced financial results for the second quarter ended June 30, 2025 and provided a corporate update.
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX)
LVTXNEW YORK, Aug. 7, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The...
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
LVTXNEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LAVA Therapeutics N.V. (NASDAQ: LVTX) to XOMA Royalty Corporation is fair to LAVA shareholders. Under the terms of the proposed transaction, XOMA Royalty will acquire LAVA for $1.16 in cash per share, plus up to $0.08 per share and a non-transferable contingent value right per share representing the right to receive 75% of the net proceeds related to LAVA’s two partnered assets and 75%
JMP Securities Reiterates Market Perform on LAVA Therapeuticsto Market Perform
LVTXLAVA Therapeutics Announced That The Netherlands Enterprise Agency (Rijksdienst Voor Ondernemend Nederland, Rvo) Granted A Full Waiver Of The Final Payment Obligation Related To The Innovation Credit, In The Amount Of $5.1M
LVTXHC Wainwright & Co. Reiterates Neutral on LAVA Therapeutics, Maintains $1.5 Price Target
LVTXLAVA Therapeutics Reports Q4 Revenues Of $4.99M, Compared With $353,000 YoY; Company Exits Quarter With Cash & Equivalents Worth $35.015M
LVTXLAVA Therapeutics Receives Nasdaq Non-Compliance Notice For Minimum Bid Price
LVTXHC Wainwright & Co. Downgrades LAVA Therapeutics to Neutral, Lowers Price Target to $1.5
LVTXLAVA Initiates Process To Review Strategic Options
LVTXTrading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
LVTXTrading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
LVTXLAVA Therapeutics Announces First Patient Dosed In Phase 1 Study Of Bispecific Anti-CD123 Gammabody LAVA-1266 For AML And MDS; Initial Data Expected By Year-End 2025
LVTXHC Wainwright & Co. Maintains Buy on LAVA Therapeutics, Lowers Price Target to $2
LVTXLAVA Therapeutics Q1 EPS $(0.02) Beats $(0.12) Estimate, Sales $6.99M Miss $7.00M Estimate
LVTXLAVA Therapeutics Q2 EPS $(0.31), Same YoY, Sales $468.00K Down From $1.08M YoY
LVTX